Recent News

• 03.30.2026 - Anavex Life Sciences Provides Comprehensive Regulatory Update
• 03.25.2026 - Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
• 03.23.2026 - Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
• 03.20.2026 - New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease
• 03.20.2026 - New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease
• 02.25.2026 - Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
• 02.25.2026 - Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
• 02.23.2026 - Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors
• 02.03.2026 - Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
• 01.13.2026 - Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease

Recent Filings

• 03.26.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.25.2026 - 8-K Current report
• 03.25.2026 - EX-99.1 EX-99.1
• 02.25.2026 - 8-K Current report
• 02.25.2026 - EX-99.1 EX-99.1
• 02.09.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 02.09.2026 - EX-99.1 EX-99.1
• 02.09.2026 - 8-K Current report
• 01.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.09.2026 - 4 Statement of changes in beneficial ownership of securities